Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 7/20 | 0.61 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14453501 | 0.89 | HSP90AA1 (0.53) | HSP90AA1HSP90AB1HDAC6HDAC1HDAC4 | |
| SCHEMBL14506409 | 0.89 | HSP90AA1 (0.53) | HSP90AA1HSP90AB1HDAC6HDAC1HDAC4 | |
| SCHEMBL14453503 | 0.89 | HSP90AA1 (0.48) | HSP90AA1HSP90AB1HDAC6HDAC1HDAC4 | |
| SCHEMBL14453496 | 0.87 | HSP90AA1 (0.69) | HSP90AA1HSP90AB1HDAC6HDAC1HDAC4 | |
| SCHEMBL3396379 | 0.80 | HSP90AB1 (0.77) | HSP90AA1HSP90AB1TRAP1 | |
| SCHEMBL14453504 | 0.78 | HSP90AA1 (0.42) | HSP90AA1HSP90AB1HDAC6HDAC1HDAC4 | |
| SCHEMBL14506406 | 0.78 | HSP90AA1 (0.54) | HSP90AA1HSP90AB1HDAC6HDAC1HDAC4 | |
| SCHEMBL14453486 | 0.77 | HSP90AA1 (0.48) | HSP90AA1HSP90AB1TRAP1 | |
| SCHEMBL14506413 | 0.76 | HSP90AA1 (0.41) | HSP90AA1HSP90AB1HDAC6HDAC1HDAC4 | |
| SCHEMBL3396006 | 0.76 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1HDAC6HDAC1HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070173483-A1 | Pyrrolopyrimidines and Related Analogs as HSP90-Inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070105874-A1 | Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105874-A1 | Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors | HSP90B1, HSP90AB1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 2/4885HDAC6 324/4885 |
| US-20070173483-A1 | Pyrrolopyrimidines and Related Analogs as HSP90-Inhibitors | HSP90AB2P, HSP90AB1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 2/4885HDAC6 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.